Does XXXX warrant @entity734 in @entity162 ?

@entity1 @entity162 @entity137 @entity1092 @entity2052 @entity734
To review the pharmacokinetic literature regarding @entity1092 ( @entity2052 ) in @entity1 with @entity162 to evaluate the appropriateness of routine @entity734 ( @entity734 ) of @entity2052 in this population. Embase, Medline, Biosis, Cumulated Index to Nursing and Allied Health Literature (CINAHL), and Cochrane Systematic Reviews databases (to July 2009) were searched (terms: @entity1092 , @entity1092 , @entity1092 , @entity1092 , @entity162 , @entity162 , @entity162 , assay, concentration, drug level, serum level, plasma level, @entity734 , drug monitoring, pharmacokinetics). A 9-step decision-making algorithm was applied to the available @entity2052 literature in the @entity162 population. @entity2052 has been established as effective first-line therapy in the treatment of @entity162 . Commercial assays are available to accurately measure @entity2052 levels with good sensitivity and precision. Wide interpatient variability in @entity2052 pharmacokinetic parameters and long anticipated treatment durations favor the use of @entity734 in the @entity162 @entity1 . Conversely, correlations between @entity2052 levels and pharmacologic response in @entity1 , and specifically @entity1 with @entity162 are unclear. Compared with other agents known to have narrow therapeutic ranges, @entity2052 does not seem to share this characteristic. Furthermore, the clinical efficacy and @entity137 of @entity2052 may be assessed in ways other than @entity734 , allowing for contributions by health care professionals, @entity1 , and family members. Despite the development of effective and widely available @entity2052 assays, routine monitoring of @entity2052 concentrations in the general @entity162 affective population does not seem warranted. However, @entity734 may enhance usual clinical monitoring in situations involving unusual @entity2052 metabolism, polytherapy with clinically relevant drug interactions, or as part of a comprehensive assessment of treatment compliance.
